Extension that converts individual Java files to Kotlin code aims to ease the transition to Kotlin for Java developers.

OpenAI has given software developers a new desktop toy, and judging by the early reactions, it might feel like someone finally handed coders the Swiss Army knife they’ve been dreaming about or the ...

For many enterprises, there continue to be barriers to fully adopting and benefiting from agentic AI. IBM is betting the blocker isn't building AI agents but governing them in production. At its ...

The Eclipse IDE is remarkably simple to install on a Windows 10 or 11 computer. To install Eclipse on Windows, simply follow the five steps outlined in this video: Download the Eclipse IDE zip file ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

A vulnerability that researchers call CurXecute is present in almost all versions of the AI-powered code editor Cursor, and can be exploited to execute remote code with developer privileges. The ...

Fintel reports that on July 30, 2025, Cantor Fitzgerald upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Overweight. Analyst Price Forecast Suggests 206.26% Upside As of July ...

For the longest time, Microsoft's VS Code has been one of the most popular IDEs (Integrated Developer Environment) on the market. It's free to use and includes all the features developers need to get ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...